Patents by Inventor Sandrina Turczynski

Sandrina Turczynski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Exon skipping therapy for dystrophic epidermolysis bullosa
    Patent number: 9340783
    Abstract: The present invention also relates to an antisense oligonucleotide complementary to a nucleic acid sequence of COL7A1 gene that is necessary for correct splicing of one or more exons which encode amino acid sequence of type VII collagen implicated in dysfunction of a mutated type VII collagen wherein said exons are selected from the group consisting of exon 73, 74 or 80 of the COL7A1 gene. The present invention also relates to a method for the treatment of a patient suffering from Dystrophic Epidermolysis Bullosa caused by a dysfunction of a mutated type VII collagen, comprising the step of administering to said patient a least one antisense oligonucleotide according to the invention.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: May 17, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DESCARTES
    Inventors: Alain Hovnanian, Matthias Titeux, Sandrina Turczynski
  • EXON SKIPPING THERAPY FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA
    Publication number: 20140288155
    Abstract: The present invention also relates to an antisense oligonucleotide complementary to a nucleic acid sequence of COL7A1 gene that is necessary for correct splicing of one or more exons which encode amino acid sequence of type VII collagen implicated in dysfunction of a mutated type VII collagen wherein said exons are selected from the group consisting of exon 73, 74 or 80 of the COL7A1 gene. The present invention also relates to a method for the treatment of a patient suffering from Dystrophic Epidermolysis Bullosa caused by a dysfunction of a mutated type VII collagen, comprising the step of administering to said patient a least one antisense oligonucleotide according to the invention.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 25, 2014
    Inventors: Alain Hovnanian, Matthias Titeux, Sandrina Turczynski